Your browser doesn't support javascript.
loading
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington, Brittney S; He, Yaowu; Davies, Claire M; Wallace, Sarah J; Adams, Mark N; Beaven, Elizabeth A; Roche, Deborah K; Kennedy, Catherine; Chetty, Naven P; Crandon, Alexander J; Flatley, Christopher; Oliveira, Niara B; Shannon, Catherine M; deFazio, Anna; Tinker, Anna V; Gilks, C Blake; Gabrielli, Brian; Brennan, Donal J; Coward, Jermaine I; Armes, Jane E; Perrin, Lewis C; Hooper, John D.
Afiliación
  • Harrington BS; Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
  • He Y; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Davies CM; Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
  • Wallace SJ; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Adams MN; Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
  • Beaven EA; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Roche DK; Mater Health Services, South Brisbane, QLD 4101, Australia.
  • Kennedy C; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Chetty NP; Mater Health Services, South Brisbane, QLD 4101, Australia.
  • Crandon AJ; Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
  • Flatley C; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Oliveira NB; Mater Health Services, South Brisbane, QLD 4101, Australia.
  • Shannon CM; Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
  • deFazio A; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Tinker AV; Department of Gynaecological Oncology, Westmead Hospital and Centre for Cancer Research, Westmead Millennium Institute, Westmead, NSW 2145, Australia.
  • Gilks CB; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Gabrielli B; Mater Health Services, South Brisbane, QLD 4101, Australia.
  • Brennan DJ; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Coward JI; Mater Health Services, South Brisbane, QLD 4101, Australia.
  • Armes JE; Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
  • Perrin LC; Mater Ovarian Cancer Research Collaborative, Mater Adult Hospital, South Brisbane, QLD 4101, Australia.
  • Hooper JD; Mater Health Services, South Brisbane, QLD 4101, Australia.
Br J Cancer ; 114(4): 417-26, 2016 Feb 16.
Article en En | MEDLINE | ID: mdl-26882065
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antígenos CD / Moléculas de Adhesión Celular / Cistadenocarcinoma Seroso / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antígenos CD / Moléculas de Adhesión Celular / Cistadenocarcinoma Seroso / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article